NCT05247268View on ClinicalTrials.gov

Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

March 10, 2027

Study Completion Date

September 10, 2027

Conditions
Endometrial Neoplasm Malignant Stage I
Interventions
DRUG

Megestrol Acetate 160 MG Oral Tablet

At a dosage of 160 mg/day

DRUG

Medroxyprogesterone Acetate 500 MG

At a dosage of 500 mg/day

DRUG

Triprorelin Acetate

Intramuscular injection of 3.75mg was given 4 weeks apart and the maximum use are 6 courses

DRUG

Letrozole 2.5mg

At a dosage of 2.5mg/day and no more than 24 weeks

Trial Locations (1)

200011

RECRUITING

Obstetrics and Gynecology Hospital, Fudan University, Shanghai

All Listed Sponsors
collaborator

Peking Union Medical College Hospital

OTHER

lead

Fudan University

OTHER